The EPS beat and positive pipeline updates (DT-216P2 trial modifications, DT-818 dosing start) are modestly bullish, but the delay in DT-168 data tempers enthusiasm. Watch for registrational plan update in Q4 2026 and 12-week RESTORE-FA data in Q1 2027 as key catalysts.
Price Chart
Executive Summary
Design Therapeutics reported Q2 2026 net loss of $0.32 per share, beating consensus of -$0.36 by 11%, and highlighted positive four-week data for DT-216P2 in Friedreich ataxia, trial modifications, and initiation of DT-818 dosing in DM1. The company maintains a strong cash position of $207.4M, but DT-168 data was delayed to 2027 due to supply issues.
Key Financial Metrics
Key Facts
- EPS of -$0.32 beat consensus of -$0.36 (11.1% beat)
- Net loss of $20.2M for Q2 2026
- Cash and securities of $207.4M as of June 30, 2026
- RESTORE-FA trial modified to evaluate 1 mpk dose with 12-week cohort; primary endpoint set as endogenous blood FXN protein percent change
- Patient dosing initiated in Phase 1 MAD trial of DT-818 for myotonic dystrophy type 1 (DM1)
- DT-168 Phase 2 biomarker trial data delayed to 2027 due to supply of eye droppers
Financial Impact
EPS beat of 11% vs consensus; net loss increased slightly YoY from $19.1M to $20.2M; cash burn rate ~$10M/month
Risk Factors
- DT-168 data delay to 2027 may signal development challenges
- Pre-revenue stage with no near-term revenue catalysts
- Clinical trial execution risk for RESTORE-FA modifications and DT-818 MAD trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3337443 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.34 (−18.97%) |
Aug 3, 2026 12w ago | Press Release | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.34 (−18.97%) |
May 18, 2026 23w ago | 8-K | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.34 (−3.36%) |
May 18, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.34 (−3.36%) |
May 17, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.34 (−3.36%) |
Apr 28, 2026 25w ago | Press Release | $15.79 $11.10 | ▼ −29.70% | ▼ −35.16% | $10.34 (−34.52%) |
Apr 23, 2026 26w ago | DEFA14A | $12.53 $11.01 | ▼ −12.13% | ▼ −16.16% | $10.34 (−17.48%) |
Apr 1, 2026 29w ago | 3 | $11.23 $13.60 | ▲ +21.10% | ▲ +11.23% | $10.34 (−7.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers